Article
Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2015
Coltella Nadia, Valsecchi Roberta, Ponente Manfredi, Ponzoni Maurilio, Bernardi Rosa
Abstract excerpt
PURPOSE: Retinoic acid-arsenic trioxide (ATRA-ATO) combination therapy is the current standard of care for patients with acute promyelocytic leukemia (APL) carrying the oncogenic fusion protein PML-RARα. Despite the high cure rates obtained with this drug combination, resistance to arsenic is recently emerging. Moreover, patients with APL carrying the PLZF-RARα fusion protein are partially resistant to ATRA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.